Search

Your search keyword '"Jingya Miao"' showing total 2 results
Start Over Author "Jingya Miao" Journal brain tumor pathology
2 results on '"Jingya Miao"'

1. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia

Author

Xiu-Wu Bian, Jingya Miao, Jing-Fang Xiao, Mianfu Cao, Xindong Liu, Yu Shi, Weiqi Dang, Qinghua Ma, Shichang Yu, Lu Chen, You-Hong Cui, Xiao-Hong Yao, and Xia Zhang

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Temozolomide, biology, Microglia, Combination therapy, business.industry, p38 mitogen-activated protein kinases, General Medicine, medicine.disease, medicine.anatomical_structure, Oncology, Integrin alpha M, PD-L1, Glioma, medicine, biology.protein, Cancer research, Neurology (clinical), Antibody, business, medicine.drug
Abstract

Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80+/CD11b+ macrophages/microglia in glioma and prolongs the survivals of glioma-bearing mice. Glioma-associated macrophages/microglia have a significanct expression of PD-L1. p38MAPK inhibitor in combination with PD-L1 antibody can effectively prolongs the survivals of TMZ-resistant GBM-bearing hosts, and differentially reduces the accumulation of circulating monocytes-derived tumor-associated macrophages and PD-L1 abundances of resident glioma-associated microglia. This combination therapy could be a treatment option for patients at the recurrence or chronic TMZ maintenance stages. A clinical study to confirm the safety and effectiveness of this combination therapy is warranted.

Published
2021
Full Text
View/download PDF

2. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia

Author

Weiqi, Dang, Jingfang, Xiao, Qinghua, Ma, Jingya, Miao, Mianfu, Cao, Lu, Chen, Yu, Shi, Xiaohong, Yao, Shichang, Yu, Xindong, Liu, Youhong, Cui, Xia, Zhang, and Xiuwu, Bian

Subjects
Antibodies, Monoclonal, p38 Mitogen-Activated Protein Kinases, B7-H1 Antigen, Gene Expression Regulation, Neoplastic, Survival Rate, Disease Models, Animal, Mice, Drug Resistance, Neoplasm, Cell Line, Tumor, Tumor-Associated Macrophages, Temozolomide, Animals, Humans, Drug Therapy, Combination, Microglia, Enzyme Inhibitors, Glioblastoma, Antineoplastic Agents, Alkylating
Abstract

Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results